Is Citius Oncology (CTOR) stock Halal?

Citius Oncology operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment. The primary function of Citius Oncology is to research and develop innovative therapies that aim to enhance the efficacy and safety profiles of current cancer treatments. The company focuses on leveraging new technology platforms and scientific advancements to address unmet medical needs in various types of cancer, impacting both the oncology and pharmaceutical sectors. For Muslim investors, though, the most pressing question is simpler: is Citius Oncology a Halal investment?

Is Citius Oncology Shariah compliant?

No. In the October 2026 screening Citius Oncology (CTOR) does not pass AAOIFI screening: it fails the non-permissible income screen. Medicines and medical devices are permissible, and healthcare companies like Citius Oncology usually clear the activity screen comfortably. What AAOIFI Shariah Standard No. 21 watches is the financing behind the pipeline: drug development is expensive, and the 30% interest bearing debt cap decides the verdict more often than the science does.

Does Citius Oncology pass the business activity test?

The activity screen is only part of the picture this month: Citius Oncology currently fails the non-permissible income screen, so the overall verdict is not compliant regardless of the business itself. Treating illness is permissible work; the scrutiny belongs to the financing behind it.

Is Citius Oncology's income Halal?

No. Citius Oncology's income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does Citius Oncology meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $107M (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has CTOR re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for Citius Oncology?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read What is Halal Investing? A Guide to Halal Stocks and Islamic Finance